A Phase 2 interventional study of Placebo and Dupilumab in Atopic Dermatitis, sponsored by Regeneron Pharmaceuticals. Completed at 21 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-10.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.
Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 24th largest by enrollment, is one of 2 that started in 2012, is one of 7 in phase 2, and was the 2nd registered.
1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.
Browse Dermatitis, Atopic studies →4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 6–17
University of California, San Francisco · Sites in United States
Ages 18+
University of Michigan · Sites in United States
Ages 18+
Sanofi
Ages 18+
By country, each count listing its studies:
dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, dupilumab is the treatment under test here. Read study by study →
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 12 · Phase 4 24
First in 2011; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 109 is above the median of 82 across 1,249 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 75 across the 50 interventional studies. Of the 38 that completed or were terminated, 26 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 50 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals: 1 open now, 2 under way, none of them phase 3. Of 27 finished, 18 (67%) have results posted.
Among the 30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals, this one is the 18th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2012, is one of 8 in phase 2, and was the 3rd registered.
Regeneron Pharmaceuticals’s Dermatitis, Atopic studies by the year they started, since 2011.
4 of the studies testing dupilumab in Dermatitis, Atopic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07905547SanofiA Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis | 2027-02-07 |
| NCT05983068SanofiA Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis | 2027-04-29 |
| NCT05042258Northwestern UniversityUsing Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis | 2027-06 |
| NCT05268107University of MichiganEthnic Differences in Mechanisms of Action of Dupilumab | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 50 studies testing dupilumab in Dermatitis, Atopic, from their registry updates:
Among Regeneron Pharmaceuticals’s 30 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
The primary objective was to assess the clinical efficacy of repeated subcutaneous (SC) doses of Dupilumab in adult participants with moderate-to-severe atopic dermatitis (AD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The inclusion criteria included, but were not limited to the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo (for Dupilumab) once weekly for 12 weeks by subcutaneous (SC) injection.
Drug: Placebo
Dupilumab 300 mg once weekly for 12 weeks by SC injection.
Drug: Dupilumab
Subcutaneous injection altered between back of arms, abdomen and upper thighs.
Subcutaneous injection altered between back of arms, abdomen and upper thighs.
Also known as: REGN668/SAR231893, Dupixent
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 12- Last Observation Carried Forward (LOCF)
The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. The efficacy data were set to be missing after use of rescue medication and after early termination visit for participants who prematurely discontinued study treatment. All missing values were imputed by LOCF.
Time frame: Baseline to Week 12
Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" at Week 12- LOCF
IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). The efficacy data were set to be missing after use of rescue medication and after early termination visit for participants who prematurely discontinued study treatment. All missing values were imputed by LOCF.
Time frame: Week 12
Percentage of Participants Who Achieved at Least a 50% Reduction From Baseline in the EASI Score (EASI-50) at Week 12- LOCF
The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-50 responders were the participants who achieved ≥50% overall improvement in EASI score from baseline to Week 12. The efficacy data were set to be missing after use of rescue medication and after early termination visit for participants who prematurely discontinued study treatment. All missing values were imputed by LOCF.
Time frame: Week 12
Change From Baseline in EASI Score at Week 12- LOCF
The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. The efficacy data were set to be missing after use of rescue medication and after early termination visit for participants who prematurely discontinued study treatment. All missing values were imputed by LOCF.
Time frame: Baseline to Week 12
Percent Change From Baseline in IGA Score at Week 12- LOCF
IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). The efficacy data were set to be missing after use of rescue medication and after early termination visit for participants who prematurely discontinued study treatment. All missing values were imputed by LOCF.
Time frame: Baseline to Week 12
Change From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis (AD) at Week 12 - LOCF
BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). It was reported as a percentage of all major body sections combined. The efficacy data were set to be missing after use of rescue medication and after early termination visit for participants who prematurely discontinued study treatment. All missing values were imputed by LOCF.
Time frame: Baseline to Week 12
Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Score at Week 12- LOCF
SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). The efficacy data were set to be missing after use of rescue medication and after early termination visit for participants who prematurely discontinued study treatment. All missing values were imputed by LOCF.
Time frame: Baseline to Week 12
Change From Baseline in Pruritus Numerical Rating Scale (NRS) to Week 12- LOCF
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). The efficacy data were set to be missing after use of rescue medication and after early termination visit for participants who prematurely discontinued study treatment. All missing values were imputed by LOCF.
Time frame: Baseline to Week 12
Change From Baseline in 5-D Pruritus Scale at Week 12
The 5-D Pruritus Scale is a 1-page, 5-question tool used in clinical trials to assess 5 dimensions of background itch: degree, duration, direction, disability, and distribution. Each question corresponds to 1 of the 5 dimensions of itch; participants were to rate their symptoms over the preceding 2-week period on a 1 to 5 scale, with 5 being the most affected. After the summation of individual score, the total score ranges from 5 (least affected) to 25 (most affected).
Time frame: Baseline to Week 12
The study was conducted at 25 sites in Europe between 3 April 2012 and 25 June 2013. A total of 153 participants were screened in the study.
| Milestone | Placebo | Dupilumab 300 mg |
|---|---|---|
| Started | 54 | 55 |
| Completed | 24 | 41 |
| Not completed | 30 | 14 |
| Withdrew: Adverse event | 3 | 1 |
| Withdrew: Physician decision | 2 | 1 |
| Withdrew: Inadequate response to study treatment | 23 | 7 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 3 |
| Withdrew: Other than specified above | 0 | 2 |
The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. The efficacy data were set to be missing after use of rescue medication and after early termination visit for participants who prematurely discontinued study treatment. All missing values were imputed by LOCF.
| percent change | Placebo | Dupilumab 300 mg |
|---|---|---|
| Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 12- Last Observation Carried Forward (LOCF) | -23.3 ± 49.26 | -74.0 ± 26.94 |
IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). The efficacy data were set to be missing after use of rescue medication and after early termination visit for participants who prematurely discontinued study treatment. All missing values were imputed by LOCF.
| percentage of participants | Placebo | Dupilumab 300 mg |
|---|---|---|
| Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" at Week 12- LOCF | 7.4 | 40.0 |
The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-50 responders were the participants who achieved ≥50% overall improvement in EASI score from baseline to Week 12. The efficacy data were set to be missing after use of rescue medication and after early termination visit for participants who prematurely discontinued study treatment. All missing values were imputed by LOCF.
| Percentage of participants | Placebo | Dupilumab 300 mg |
|---|---|---|
| Percentage of Participants Who Achieved at Least a 50% Reduction From Baseline in the EASI Score (EASI-50) at Week 12- LOCF | 35.2 | 85.5 |
The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. The efficacy data were set to be missing after use of rescue medication and after early termination visit for participants who prematurely discontinued study treatment. All missing values were imputed by LOCF.
| Units on a scale | Placebo | Dupilumab 300 mg |
|---|---|---|
| Change From Baseline in EASI Score at Week 12- LOCF | -6.4 ± 14.85 | -19.9 ± 11.52 |
IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). The efficacy data were set to be missing after use of rescue medication and after early termination visit for participants who prematurely discontinued study treatment. All missing values were imputed by LOCF.
| Percent change | Placebo | Dupilumab 300 mg |
|---|---|---|
| Percent Change From Baseline in IGA Score at Week 12- LOCF | -14.7 ± 27.37 | -49.5 ± 25.94 |
BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). It was reported as a percentage of all major body sections combined. The efficacy data were set to be missing after use of rescue medication and after early termination visit for participants who prematurely discontinued study treatment. All missing values were imputed by LOCF.
| Percentage of BSA | Placebo | Dupilumab 300 mg |
|---|---|---|
| Change From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis (AD) at Week 12 - LOCF | -9.0 ± 21.07 | -27.4 ± 22.81 |
SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). The efficacy data were set to be missing after use of rescue medication and after early termination visit for participants who prematurely discontinued study treatment. All missing values were imputed by LOCF.
| Units on a scale | Placebo | Dupilumab 300 mg |
|---|---|---|
| Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Score at Week 12- LOCF | -9.8 ± 20.53 | -35.0 ± 19.43 |
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). The efficacy data were set to be missing after use of rescue medication and after early termination visit for participants who prematurely discontinued study treatment. All missing values were imputed by LOCF.
| units on a scale | Placebo | Dupilumab 300 mg |
|---|---|---|
| Change From Baseline in Pruritus Numerical Rating Scale (NRS) to Week 12- LOCF | -0.9 ± 2.07 | -3.5 ± 2.00 |
The 5-D Pruritus Scale is a 1-page, 5-question tool used in clinical trials to assess 5 dimensions of background itch: degree, duration, direction, disability, and distribution. Each question corresponds to 1 of the 5 dimensions of itch; participants were to rate their symptoms over the preceding 2-week period on a 1 to 5 scale, with 5 being the most affected. After the summation of individual score, the total score ranges from 5 (least affected) to 25 (most affected).
| units on a scale | Placebo | Dupilumab 300 mg |
|---|---|---|
| Change From Baseline in 5-D Pruritus Scale at Week 12 | -1.9 ± 4.28 | -7.4 ± 4.33 |
Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Day 197) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 7/54 (13%) | 31/54 (57.4%) |
| Dupilumab 300 mg | — | 1/55 (1.8%) | 38/55 (69.1%) |
| Event | Placebo | Dupilumab 300 mg |
|---|---|---|
| Dermatitis atopicSkin and subcutaneous tissue disorders | 4/54 | 0/55 |
| Angina pectorisCardiac disorders | 1/54 | 0/55 |
| CellulitisInfections and infestations | 1/54 | 0/55 |
| Eczema herpeticumInfections and infestations | 1/54 | 0/55 |
| Skin bacterial infectionInfections and infestations | 1/54 | 0/55 |
| Renal failureRenal and urinary disorders | 1/54 | 0/55 |
| Asthmatic crisisRespiratory, thoracic and mediastinal disorders | 1/54 | 0/55 |
| Lung disorderRespiratory, thoracic and mediastinal disorders | 1/54 | 0/55 |
| Facial bones fractureInjury, poisoning and procedural complications | 0/54 | 1/55 |
| Event | Placebo | Dupilumab 300 mg |
|---|---|---|
| NasopharyngitisInfections and infestations | 10/54 | 22/55 |
| HeadacheNervous system disorders | 7/54 | 9/55 |
| ConjunctivitisInfections and infestations | 2/54 | 8/55 |
| Conjunctivitis allergicEye disorders | 0/54 | 5/55 |
| FatigueGeneral disorders | 4/54 | 5/55 |
| Injection site indurationGeneral disorders | 3/54 | 5/55 |
| LymphadenopathyBlood and lymphatic system disorders | 4/54 | 0/55 |
| NauseaGastrointestinal disorders | 4/54 | 1/55 |
| Injection site erythemaGeneral disorders | 1/54 | 4/55 |
| EosinophiliaBlood and lymphatic system disorders | 3/54 | 0/55 |
| Age, Continuous(years) | Placebo | Dupilumab 300 mg | Total |
|---|---|---|---|
| Mean | 39.4 ± 12.29 | 33.7 ± 10.41 | 36.5 ± 11.69 |
| Sex: Female, Male(Participants) | Placebo | Dupilumab 300 mg | Total |
|---|---|---|---|
| Female | 27 | 24 | 51 |
| Male | 27 | 31 | 58 |
| Eczema Area and Severity Index (EASI) Score(units on a scale) | Placebo | Dupilumab 300 mg | Total |
|---|---|---|---|
| Mean | 30.8 ± 13.63 | 28.4 ± 13.57 | 29.6 ± 13.59 |
| Investigator's Global Assessment (IGA) Score(units on a scale) | Placebo | Dupilumab 300 mg | Total |
|---|---|---|---|
| Mean | 4.0 ± 0.69 | 3.9 ± 0.67 | 3.9 ± 0.68 |
| Scoring Atopic Dermatitis (SCORAD) Score(units on a scale) | Placebo | Dupilumab 300 mg | Total |
|---|---|---|---|
| Mean | 69.1 ± 13.38 | 66.7 ± 13.82 | 67.9 ± 13.59 |
| Body Surface Area (BSA)(percentage of BSA) | Placebo | Dupilumab 300 mg | Total |
|---|---|---|---|
| Mean | 50.8 ± 24.13 | 46.8 ± 24.55 | 48.8 ± 24.32 |
| 5-D Pruritus Scale(units on a scale) | Placebo | Dupilumab 300 mg | Total |
|---|---|---|---|
| Mean | 18.7 ± 3.50 | 18.4 ± 3.04 | 18.5 ± 3.26 |
| Pruritus Numerical Rating Scale (NRS) Score(units on a scale) | Placebo | Dupilumab 300 mg | Total |
|---|---|---|---|
| Mean | 5.8 ± 1.93 | 6.1 ± 1.34 | 5.9 ± 1.66 |
The record gives a start of Apr 2012, a primary completion of Mar 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2018, 5 years 5 months after primary completion. A results delay was requested in Aug 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab